Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ASTRAZENECA PHARMA DISHMAN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 25.1 152.3 16.5% View Chart
P/BV x 3.3 42.8 7.8% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-18
DISHMAN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,278 29.3%   
Low Rs129883 14.6%   
Sales per share (Unadj.) Rs197.8228.4 86.6%  
Earnings per share (Unadj.) Rs21.210.4 204.6%  
Cash flow per share (Unadj.) Rs34.716.3 213.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.998.8 182.1%  
Shares outstanding (eoy) m80.6925.00 322.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.7 26.9%   
Avg P/E ratio x11.9104.2 11.4%  
P/CF ratio (eoy) x7.266.4 10.9%  
Price / Book Value ratio x1.410.9 12.8%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30627,008 75.2%   
No. of employees `0000.81.4 61.1%   
Total wages/salary Rs m5,3551,535 348.8%   
Avg. sales/employee Rs Th19,252.74,210.9 457.2%   
Avg. wages/employee Rs Th6,459.51,132.2 570.5%   
Avg. net profit/employee Rs Th2,064.1191.1 1,080.2%   
INCOME DATA
Net Sales Rs m15,9615,710 279.5%  
Other income Rs m265123 216.7%   
Total revenues Rs m16,2265,833 278.2%   
Gross profit Rs m4,103463 886.4%  
Depreciation Rs m1,091147 739.9%   
Interest Rs m9440-   
Profit before tax Rs m2,334438 532.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624179 348.6%   
Profit after tax Rs m1,711259 660.4%  
Gross profit margin %25.78.1 317.1%  
Effective tax rate %26.740.8 65.4%   
Net profit margin %10.74.5 236.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,209 343.3%   
Current liabilities Rs m9,5172,070 459.9%   
Net working cap to sales %9.420.0 47.1%  
Current ratio x1.21.6 74.7%  
Inventory Days Days11072 152.7%  
Debtors Days Days3535 99.8%  
Net fixed assets Rs m16,304790 2,063.0%   
Share capital Rs m16150 322.8%   
"Free" reserves Rs m12,9072,419 533.5%   
Net worth Rs m14,5162,469 587.8%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8054,605 647.2%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.2 43.2%   
Return on assets %8.95.6 158.4%  
Return on equity %11.810.5 112.3%  
Return on capital %17.517.7 98.8%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,952300 1,653.0%   
Fx outflow Rs m6972,015 34.6%   
Net fx Rs m4,255-1,715 -248.0%   
CASH FLOW
From Operations Rs m2,78688 3,170.0%  
From Investments Rs m-1,529-94 1,633.4%  
From Financial Activity Rs m-941NA-  
Net Cashflow Rs m316-6 -5,550.9%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 15.7 80.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 12,856 359.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  SUVEN LIFE SCIENCES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS